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Background. Reactive oxygen species- (ROS-) mediated ischemia-reperfusion injury (IRI) detrimentally impacts liver
transplantation and resection. 12/15-Lipoxygenase (12/15-LOX), an antagonistic protein of the glutathione peroxidase 4 (GPX4)
signaling cascade, was proven to mediate cell death in postischemic cerebral and myocardial tissue. The aim of this study was to
investigate the impact of 12/15-LOX inhibition on hepatic IRI. Methods. Livers of C57BL/6 mice were exposed to 60 minutes of
partial warm ischemia and 90 minutes of reperfusion after previous Baicalein administration, an inhibitor of 12/15-LOX. Tissue
samples were analyzed by TUNEL assay, Western blot, and spectral photometry. Results. TUNEL labeling showed a signiﬁcant
reduction of hepatic cell death following baicalein pretreatment. Western Blot analysis revealed a signiﬁcant downregulation of
Jun-amino-terminal-kinase (JNK), caspase-3, and poly-ADP-ribose-polymerase (PARP), besides considerably lowered p44/42-
MAP-kinase (ERK1/2) expression after Baicalein administration. A signiﬁcant elevation of glutathione oxidation was measured
in Baicalein pretreated livers. Conclusion. Our data show that inhibition of 12/15-lipoxygenase causes signiﬁcant cell death
reduction after hepatic ischemia and reperfusion by enhancing glutathione metabolism. We conclude that GPX4-dependent cell
death signaling cascade might play a major role in development of hepatic IRI, in which the investigated proteins JNK, caspase-
3, ERK1/2, and PARP might contribute to tissue damage.
1. Introduction
Hepatic ischemia-reperfusion injury (IRI) is associated with
signiﬁcant morbidity and mortality and occurs during liver
resection, transplantation, and trauma, as well as septic and
hemorrhagic shock [1–3]. IRI is characterized by a complex
cascade of intracellular signaling processes leading to diﬀer-
ent forms of cell death mainly due to reoxygenation during
reperfusion (oxidative stress) [4, 5]. These include spontane-
ous and programmed cell death with or without initiating an
inﬂammatory response, deﬁned by the morphological or bio-
chemical behavior of the cell andmay be commonly classiﬁed
as apoptosis, necrosis, necroptosis, and ferroptosis. Partial
overlapping and the simultaneous occurrence of the diﬀerent
forms of cell death are known to be possible [6–8]. In recent
years, newly detected nonapoptotic forms of cell death, most
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notably ferroptosis, became more and more important in
understanding the complex characteristics of cell death
[9–11]. By all means, the accumulation of reactive oxygen
species (ROS) inducing oxidative stress represents a strong
inducer for many forms of cell death [9, 12–14]. This ROS-
mediated liver damage not only leads to limited postopera-
tive liver function but is also regarded as an immediate origin
of allograft rejection, delayed graft function, and primary
nonfunction after liver transplantation [2, 15]. Therefore,
several antioxidant treatments are currently under investiga-
tion to improve the outcome after liver transplantation [16].
Among the proposed mechanisms of oxidative stress,
uncontrolled lipid peroxidation may represent a link
between intracellular reactive oxygen species and membrane
disruption [17–19], which is by a major part mediated by
mitochondrial permeability transition [8, 20]. 12/15-Lipoxy-
genase (12/15-LOX) has been considered to be a relevant
source of lipid peroxidation in IRI models, as it deoxygenates
membrane-bound arachidonic acid—most importantly in
mitochondrial membranes [21]—into 12S/15S-HpETE
(12S/15S-hydroperoxyeicosatetraenoic acid) [22] which is
one of the key metabolites to induce cell death after induction
of IRI [23]. Glutathione peroxidase 4 (GPX4) may be
regarded as cell protective and functionally antagonistic to
12/15-LOX in IRI, as it is the only GPX to process phospho-
lipid hydroperoxides in membranes [24], thus being able to
reduce 12S/15S-HpETE into 12S/15S-HETE (12S/15S-
hydroxyeicosatetraenoic acid) which will not trigger further
cell death [23]. These ﬁndings were supported by cell-based
experiments showing that treating GPX4−/− cells with
HpETE led to signiﬁcantly accelerated loss of cell viability
whereas the addition of HETE had no impact on cell death
[25]. Furthermore, it has been shown that GPX4 activity itself
can be inhibited by sustained oxidative stress as intracellular
stores of reduced glutathione are oxidized resulting in GPX4
inhibition, increased lipid peroxidation, and cell death [26].
This mechanism has been reconﬁrmed in vivo in several
models after neuronal [27–29] and myocardial ischemia
and reperfusion [30]. In a murine experimental model, mice
overexpressing GPX4 are protected against oxidative stress
[31], and administration of glutathione, the main substrate
of GPX4, attenuates IRI after warm ischemia [32, 33]. These
results were furthermore conﬁrmed by Shang et al. providing
evidence in 2016 that impaired glutathione biosynthesis was
associated with a higher level of oxidative stress and hence
with a higher impact of IRI on liver damage [34]. Analysis
of the downstream pathway using selective knockout mice
showed that GPX4 controls lipid peroxidation presumably
via regulation of 12/15-lipoxygenase activity which in turn
was shown to contribute to cell death [26].
Lipid peroxidation during oxidative stress in hepatic IRI
has been attributed to the activity of 5-lipoxygenase [35].
Therefore, 5-lipoxygenase inhibitors have been investigated
in detail throughout recent years and have been shown to
reduce the postischemic leukotriene-mediated hepatic injury,
mainly by reduction of leukotriene B4 [36–38]. However, in
contrast, little is known about the role of the 12/15-lipoxy-
genase signaling system and its downstream mediators on
cell death following hepatic ischemia and reperfusion,
although inhibition of 12/15 lipoxygenase is feasible by
administration of the antioxidant Baicalein, a ﬂavonoid
which is contained in the Japanese herbal supplement Sho-
saiko-to and whose interventional potential as an antioxidant
has been investigated for several years [39–41].
Therefore, the present study aimed at investigating the
impact of the 12/15 lipoxygenase inhibition with Baicalein
on cell death induction after experimental hepatic ischemia
and reperfusion in the mouse.
2. Material and Methods
2.1. Experimental Model and Technique. For all experiments,
6- to 8-week-old male C57BL/6 wild-type mice (Charles
River, Sulzfeld, Germany) were used. All experiments were
carried out according to the German legislation on protec-
tion of animals under the Protocol number 55.2.1.54-2532-
100-11. The surgical procedure and experimental protocol
were performed in dependence on the techniques described
by Hori et al. in 2011 [42].
Brieﬂy, under commonly used anaesthesia with midazo-
lam, medetomidine, and fentanyle, a polypropylene catheter
was inserted into the right carotid artery in a retrograde
direction for measurement of mean arterial pressure and
heart rate, as well as for volume substitution with normal
saline. A warm (37°C) reversible ischemia of the right ante-
rior, left anterior, and left posterior liver segment was
induced for 60min by clamping the common supplying ped-
icle using a microclip beginning 10min after laparotomy,
resulting in an ischemic fraction of 65% of the liver [42].
Reperfusion time was 90min in all experiments. Three IR
groups and three corresponding sham-operated groups were
analyzed (n = 10 each).
Baicalein, the inhibitor of 12/15-LOX (Merck, Germany),
was administered intraperitoneally 30 minutes before lapa-
rotomy, in order to allow a well-established duration for ade-
quate peritoneal drug distribution and absorption [43, 44].
The dosage was 120mg/kg body weight (group 1), equaling
an injected volume of 150μl at maximum solubility in
dimethylsulfoxide (DMSO) according to manufacturer’s
instructions. To avoid objectionable interactions caused by
rise of intra-abdominal pressure, the intraperitoneally
administered volume did not exceed the limits recommended
for laboratory animal care [45, 46]. Controls were treated
either with a corresponding volume of the vehicle (DMSO;
AppliChem, Germany) (group 2) or left untreated, receiving
a corresponding volume of saline intraperitoneally (group 3).
Blood samples were taken from the vena cava at the end
of the experiment and immediately centrifuged at 2000×g
for 10 minutes. The obtained serum was immediately stored
at −80°C. Tissue specimens from I/R and non-I/R liver lobes
were collected at 90 minutes after reperfusion for histological
investigations and Western blot analyses.
2.2. Serum Analyses. Serum bilirubin, creatinine, cholin-
esterase, glutamate dehydrogenase (GLDH), aspartate
aminotransferase (AST), and alanine aminotransferase
(ALT) activities were determined at 37°C with an auto-
mated analyzer (Hitachi 917, Roche-Boehringer, Germany)
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using standardized test systems (ALAT-FS, ASAT-FS,
Bilirubin Auto Total-FS, Creatinine-FS, GLDH-FS-DGKC,
DiaSys, Germany).
2.3. TUNEL Assay. Cells undergoing cell death were quanti-
ﬁed in formalin-ﬁxed and paraﬃn-embedded tissue slices of
the hepatic left posterior segment, harvested as described
above. TUNEL staining was performed using an “In Situ
Cell Death Detection Kit, POD” (Roche, Switzerland)
according to the manufacturer’s instructions. Counterstain-
ing to visualize DNA fragmentation was performed using
the 4′,6-diamidino-2-phenylindole technique (DAPI, Vector
Laboratories Inc., USA). Quantiﬁcation of TUNEL-positive
cells was performed by means of planimetric analyses of
labeled cells with ﬂuorescence microscopy using an emission
wavelength of 450–500nm and ﬂuorescence detection at
515–565nm (green light). 10 randomly selected regions
of interest (ROI) of each tissue slice were analyzed sepa-
rately under 10x enlargements. The microscopic images
gained by this manner were consecutively processed using
ImageJ (National Institutes of Health, USA), thus allowing
the software to automatically detect and calculate the area
fraction of TUNEL-positive cells for each group as a direct
proportional parameter for dead cell count. All histological
examinations were performed by one of the authors in a
blinded manner.
2.4. Western Blot. Western blots were used for detection of
proapoptotic protein levels in the liver lobes undergoing
ischemia reperfusion injury. Tissue of the hepatic right ante-
rior segment was minced in buﬀer containing 1μl/ml dithio-
threitol (DTT, Sigma-Aldrich, USA) and 10μl/ml protease
inhibitor mixture containing aprotinin (100U/ml, Sigma-
Aldrich, USA). Protein concentration in each hepatic tissue
lysate was determined using a “Pierce™ BCA Protein Assay
Kit” (ThermoFisher Scientiﬁc, USA). SDS-gel electrophoresis
and protein transfer onto nitrocellulose membranes and
followed by overnight incubation with antibodies at 4°C
were performed for activity detection of stress-activated
protein kinase/Jun-amino-terminal kinase (SAPK/JNK, rab-
bit, 46/54 kDa, Cell Signaling Technology, USA), mitogen-
activated protein kinase p44/42 (ERK1/2, rabbit, 42/44 kDa,
Cell Signaling Technology, USA), caspase-3 (rabbit, 17/19/
35 kDa, Cell Signaling Technology, USA), and poly-ADP-
ribose-polymerase (PARP, rabbit, 89/116 kDa, Cell Signal-
ing Technology, USA). ERK1/2 and SAPK/JNK antibodies
were analyzed by blotting their respective phosphorylated
and total fractions; all Western blots were blotted a second
time using a glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) antibody (rabbit, 37 kDa, Cell Signaling Techno-
logy, USA) in order to achieve a reliable loading control.
All Western blots were processed using an HRP-linked
antibody (anti-rabbit IgG, Cell Signaling technology,
USA) as secondary antibody. Blotted results were visualized
by chemiluminescence technique (SuperSignal, Thermo-
Fisher Scientiﬁc, USA).
2.5. Measurement of GSH and GSSG. Intracellular concentra-
tions of glutathione (GSH) and its oxidized state glutathione
disulﬁde (GSSG) were analyzed applying spectral photome-
try and a kinetic test ﬁrst described by Tietze in 1969 [47].
Tietze’s test was performed with tissue of shock frozen liver
lobes that underwent IRI and were lysed by adding perchloric
acid and ethylenediaminetetraacetic acid (EDTA). Protein
precipitate was consecutively removed from the centrifuged
tissue homogenate. In the following procedure, the total glu-
tathione concentration was determined by measuring the
velocity of thionitrobenzoic acid (TNB) accumulation with
spectral photometry at 412nm representing the product
of a spontaneous reaction between GSH within the tissue
sample (hepatic right anterior segment) and 5,5-dithiobis-
nitrobenzoic acid (DTNB), which was added to the stan-
dardized reaction. This velocity is directly proportional to
the total glutathione concentration (GSH+GSSG) in the
sample. GSSG concentration could be determined using
the same testing mechanism as described above, yet after
preventing autooxidation of GSH to GSSG by adding N-
ethylmaleimide (NEM). NEM conjugates GSH potently as
ﬁrst described by Tietze and furtherly developed by Lau-
terburg et al. in 1984 [48]. Accordingly, intracellular con-
centration of GSH can be calculated by subtracting
measured GSSG levels from total glutathione levels. Using
this technique, both substrate and product of GSH metab-
olizing selenoperoxidases can be estimated indirectly,
among which GPX4 plays a distinct role as suggested by
others and described above.
2.6. Statistical Analysis. Statistics and ANOVA were calcu-
lated using Brown-Forsythe test, Bartlett’s test, Fisher’s
LSD-test, and Dunnett’s & Tukey’s multiple comparisons test
(GraphPad Prism 7, GraphPad Software, San Diego, USA).
Mean values± SEM are given. P values less than 0.05 were
considered signiﬁcant.
3. Results
3.1. Eﬀects of Baicalein and DMSO Pretreatment on
Macrohemodynamics. Assessment of macrohemodynamics
has been performed throughout the entire experiment via
intra-arterial measuring of blood pressure and heart rate.
Obvious diﬀerences between the experimental groups could
not be observed throughout the majority of the duration of
the experiment. Solely at the beginning of the experiment,
directly after cannulation of the carotid artery and thereby
immediately after drug administration, a signiﬁcant change
in hemodynamics could be monitored for a considerably
short period of time (Figure 1). At this time point, after sole
DMSO pretreatment, the blood pressure was by −35.4% sig-
niﬁcantly lower (p < 0 001) and the heart rate was signiﬁ-
cantly higher (+93.7%; p < 0 001) compared to the control
group. No signiﬁcant alteration was recorded after additional
Baicalein application. Within the following ﬁve minutes,
both blood pressure and heart rate aligned among the diﬀer-
ent groups, so that no signiﬁcant diﬀerences could be moni-
tored. A dip of blood pressure ﬁve minutes after reperfusion
of the liver was observed in each experimental group repeat-
edly, representing a loss of systemic blood volume into the
reperfusing liver lobes. This proved to be a quickly self-
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adjusting process as the decrease of blood pressure resolved
within approx. two minutes (Figure 1).
3.2. Eﬀects of Baicalein and DMSO Pretreatment on Cell
Death after Hepatic Ischemia and Reperfusion. Analyses of
hepatic tissue samples processed with TUNEL assay after
inducing an ischemia reperfusion injury as described above
revealed relevant diﬀerences in loss of cell viability between
the groups (Figure 2). Baicalein pretreatment resulted in a
signiﬁcant decrease in area fraction of the TUNEL-positive
signals within the liver tissue by −64.8% in contrast to the
control group (p = 0 0007). Interestingly, a slight decrease
in cell death could also be demonstrated after the sole
application of the vehicle for Baicalein, DMSO by −23.2%.
This result, however, did not reach statistical signiﬁcance.
Even though taking the slight decrease of cell death induced
by the sole application of DMSO into account, the prevention
of cell death by Baicalein remained evident, as TUNEL-
positive cell count in the Baicalein group was signiﬁ-
cantly lowered by −54.1% in contrast to the DMSO group
(p = 0 0471). Therefore, these data suggest that cell death
after hepatic ischemia and reperfusion is signiﬁcantly
lowered by Baicalein administration.
3.3. Eﬀects of Baicalein and DMSO Pretreatment on
Proapoptotic Enzyme Pathways. Potential molecular path-
ways leading to diﬀerences in cell death responses as men-
tioned above have been analyzed by measuring several
proapoptotic enzyme levels within the liver tissue that under-
went ischemia and reperfusion. These measurements indeed
revealed distinctive diﬀerences in enzyme activity levels
between the diﬀerent experimental groups (Figure 3).
Mitogen-activated protein kinase p44/42 (ERK) activity
was evaluated as a ratio of activated phosphorylated ERK
over the total measurable ERK amount. A discrete nega-
tive regulatory trend by −36.7%, though statistically not
signiﬁcantly, could be monitored in the activation of
ERK after Baicalein pretreatment, whereas the vehicle DMSO
showed no inﬂuence.
Administration of Baicalein also resulted in a −73.8%
signiﬁcantly lower activity of PARP (poly-ADP-ribose-
polymerase), measured as a quotient of cleaved—thus activa-
ted—PARP over uncleaved PARP, compared to the control
group (p = 0 0307). Concurrently, a signiﬁcant downregula-
tion of PARP activity by −68.8% after sole DMSO application
could be monitored (p = 0 0435).
In contrast, caspase-3 activation was found to be slightly
upregulated after DMSO application, albeit statistically not
signiﬁcantly. Baicalein pretreatment, however, led to a
highly signiﬁcant decrease in caspase-3 activity by −45.0%
compared to the control group (p = 0 004). Hence, our data
suggest that the antiapoptotic eﬀect of Baicalein by downreg-
ulation of caspase-3 can be estimated to be even higher due to
the primary elevation of caspase-3 activity by its vehicle
DMSO. Comparing the results of the Baicalein group to those
of the DMSO group expectedly showed an even more distinct
and signiﬁcant decrease in the level of active caspase-3
(−56.4%, p = <0 0001).
The ratio of phosphorylated JNK (Jun-amino-terminal
kinase) versus total JNK expression in liver tissue correlates
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Figure 1: Measurements of macrohemodynamics while inducing ischemia and reperfusion in the liver throughout the experiment. Intra-
arterial measurements of blood pressure (a) and heart rate (b) revealed a brief decrease in mean arterial blood pressure by 35.4% at the
beginning of the experiment after Baicalein administration and after sole DMSO pretreatment (−34.4%) compared to the control. A heart
rate elevation at the same time point by 104.2% (Baicalein) and 93.7% (DMSO) compared to control could also be measured. In further
progress, no signiﬁcant diﬀerences in macrohemodynamics between the groups could be monitored. A self-limiting decrease of blood
pressure ﬁve minutes after reperfusion could repeatedly be observed in all groups. Data are presented as the mean± SEM.
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with JNK activity. After Baicalein pretreatment, a decrease of
JNK activity could be evaluated by −82.6%, representing a
highly signiﬁcant result (p = 0 0049). Also, the sole vehicle
administration of DMSO resulted in a signiﬁcantly lowered
JNK activity, yet not as signiﬁcantly as in combination with
Baicalein (−68.9%, p = 0 0222).
In summary, Baicalein aﬀected several diﬀerent pro-cell
death pathways after hepatic IRI in an inhibiting manner.
3.4. Eﬀects of Baicalein and DMSO Pretreatment on Liver
Damage Parameters in Blood. Potential toxicity of admin-
istered drugs and systemic liver response was investigated
by evaluating serum levels of several liver enzymes, biliary
excretion, and hepatic synthesis parameters, as well as
renal function. No signiﬁcant diﬀerences in serum levels
of creatinine, bilirubin, or cholinesterase could be found
between the groups, neither after sham operation nor after
inducing IRI (Table 1). However, after application of Bai-
calein and DMSO solely, a distinct increase in serum levels
of AST, ALT, and GLDH could be observed both in sham-
operated mice and in those after hepatic ischemia and
reperfusion. For further evaluation, the factor by which
an administered agent elevates the amount of liver enzyme
release in pretreated and subsequently sham-operated mice
compared to the sham-operated control group without
pretreatment was calculated. This has been performed for
each of the liver enzymes mentioned above and described
as the particular toxic factor (Figure 4). Therefore, it could
be shown that AST levels were elevated by 3.13-fold, ALT
levels by 1.01-fold, and GLDH levels by 5.18-fold after
Baicalein pretreatment. DMSO administration showed an
increase in enzyme levels by a factor of 1.08 for AST,
1.22 for ALT, and 1.72 for GLDH. After inducing hepatic
IRI, a relevant increase of liver enzymes could also be
measured in each group (Table 1). Further, it has been
evaluated whether the toxic factor described above could
be attenuated by a potential hepatoprotective eﬀect of the
administered drugs after inducing IRI by calculating a
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Figure 2: TUNEL assay of liver tissue (left posterior segment) exposed to ischemia-reperfusion injury. Representative images of TUNEL
stainings demonstrating the diﬀerences in cell death after no/saline pretreatment (a), pretreatment with DMSO (b), and pretreatment with
Baicalein (c). Quantitive planimetric analyses of TUNEL positive cells conﬁrm a signiﬁcant reduction of cell death after Baicalein
pretreatment (Baicalein versus control by −64.8%, ∗∗∗p = 0 0007; Baicalein versus vehicle DMSO by −54.1%, ∗p = 0 0471) (d). Data are
presented as the mean± SEM.
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relative liver enzyme decrease. Therefore, a ratio of the
calculated toxic factor after IRI over the previously evalu-
ated toxic factor of the respective sham group as described
above was generated. Again, this has been performed for
each pretreatment drug and each liver enzyme to be scru-
tinized. Thus, the toxic factor of an administered drug for
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Figure 3: Western blot assays of liver tissue (right anterior segment) exposed to ischemia-reperfusion injury for detection of activity levels of
proapoptotic proteins JNK (stress-activated protein kinase/Jun-amino-terminal kinase), ERK (mitogen-activated protein kinase p44/42),
caspase-3, and PARP (poly-ADP-ribose-polymerase). (a) Representative images of Western blots demonstrating the diﬀerences in enzyme
activity levels for each experimental group. Inactive proteins are shown on top for ERK (total ERK, 42 + 44 kDa), PARP (uncleaved,
116 kDa), caspase-3 (loading control GAPDH, 37 kDa), and JNK (total JNK, 46 + 54 kDa). Activated protein forms are shown in the
middle for ERK (phosphorylated ERK, 42 + 44 kDa), PARP (cleaved, 89 kDa), caspase-3 (cleaved, 20 kDa), and JNK (phosphorylated JNK,
46 + 54 kDa). Loading controls are shown below in each group for glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 37 kDa). (b)
Quantitative photometric analyses of Western blots prove the mostly signiﬁcant downregulation of proapoptotic enzyme activity
levels after Baicalein pretreatment. Activated enzyme ratio is calculated as a quotient of active/inactive protein form. Changes in
protein level activation after sole vehicle administration (DMSO) could also be observed. Data are presented as the mean± SEM.
∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001.
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one speciﬁc enzyme in the sham group represents a rel-
ative toxic factor of 100% for the respective evaluation
after inducing IRI. Using this method, a signiﬁcant
attenuation of liver enzyme increase following Baicalein
pretreatment by −50.3% for AST (p = 0 0438) and −65.8%
for GLDH (p = 0 0481) as well as a negative regulatory
trend of −15.4% for ALT could be observed after hepatic
IRI. DMSO administration led to a −38.0% decrease of
elevated AST, −60.0% of ALT, and −56.0% of GLDH
release. Therefore, it can be stated that DMSO and Baica-
lein pretreatment cause an elevated release of liver
enzymes AST, ALT, and GLDH after both sham operation
and hepatic IRI, whereas the increase is clearly attenuated
after IRI induction.
3.5. Eﬀects of Baicalein and DMSO Pretreatment on
Glutathione Hemostasis. The direct inﬂuence of the adminis-
tered agents Baicalein and DMSO on glutathione-dependent
peroxidases was evaluated by measuring its substrate GSH
and its product GSSG and subsequently calculating a quotient
of GSSG over GSH as an indirect measure of glutathione per-
oxidase activity. The pretreatment with Baicalein resulted in
a signiﬁcant intrahepatic elevation of glutathione oxidation
by 54.5% (p = 0 0438) (Figure 5). Relevant diﬀerences in acti-
vation could be monitored between Baicalein and its vehicle,
as the sole application of DMSO led to an increase of glutathi-
one oxidation by notmore than 16.7%. Even though this result
couldnotbeproven tobe statistically signiﬁcant, apositive reg-
ulatory trend of DMSO on glutathione peroxidase activity
Table 1: Serum analyses.
Sham IRI
Control DMSO Baicalein Control DMSO Baicalein
Creatinine (mg/dl) 0.8± 0 0.8± 0 0.8± 0 0.8± 0.0001 0.8± 0.0001 0.8± 0.0001
Bilirubin (mg/dl) 0.9± 0.1 1.1± 0.3 1.0± 0.2 1.1± 0.2 1.4± 0.3 1.3± 0.1
Cholinesterase (kU/l) 2.9± 0.1 3.2± 0.2 3.5± 0.2 2.9± 0.1 3.3± 0.1 3.3± 0.2
AST (U/l) 152.0± 34.3 315.8± 65.4 627.0± 102.0 697.2± 180.7 1162.8± 310.5 1780.5± 455.7
ALT (U/l) 121.0± 26.5 269.0± 73.781 243.0± 78.1 860.0± 291.7 1280.8± 427.0 1593.1± 626.9
GLDH (U/l) 14.5± 3.8 39.5± 18.3 89.8± 21.1 131.3± 25.7 230.3± 68.3 363.8± 132.9
Data presented as mean ± SEM. No signiﬁcant diﬀerences between all groups could be stated regarding creatinine, bilirubin, and cholinesterase values. A
relevant elevation of hepatic damage enzymes could be observed after Baicalein and sole DMSO application compared to the respective control in both
Sham and IRI groups.
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Figure 4: Quantitative serum analyses of caval blood gained after inducing hepatic IRI or, respectively, after sham operation. (a)
Quantiﬁcation of the increase of liver enzymes in sham-operated mice after DMSO and Baicalein administration by calculating the toxic
factor. The toxic factor is calculated as a ratio of enzyme elevation after drug administration compared to the control group over the
control group itself. The data show that Baicalein and DMSO administration relevantly increase AST, ALT, and GLDH levels. (b)
Assessment of attenuation of the liver enzyme elevation post DMSO and Baicalein pretreatment after inducing hepatic IRI by calculating a
relative increase in enzyme activation. This is generated as ratio of the calculated toxic factor after IRI over the previously calculated toxic
factor of the respective sham-operated mice. Therefore, the relative enzyme increase for the sham group matches 100% for each enzyme
and pretreatment to be investigated. Hence, it can be stated that Baicalein pretreatment after IRI leads to an acknowledgeable decrease of
liver enzyme elevation compared to the respective sham-operated mice, signiﬁcant for AST activation (−50.3%; ∗p = 0 0438) and GLDH
activation (−65.8%; ∗p = 0 0481).
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could be speculated. However, a signiﬁcant direct impact of
Baicalein pretreatment towards upregulation of oxidative
glutathione consumption could be monitored.
4. Discussion
Hepatic IRI is one of the most common causes for organ dys-
function and failure after orthotopic liver transplantation
(OLT) and may compromise the outcome after extended
liver resections and OLT [15, 16, 49]. Therefore, strategies
to minimize the negative eﬀects of ischemia are now in the
forefront of clinical and experimental studies. After the atten-
uation of the eﬀects of cold ischemia in OLT has been a cru-
cial approach in transplant research for a long period, warm
ischemia has attracted considerable interest throughout
recent years as it is known to aﬀect predominantly parenchy-
mal liver cells and biliary injury [50–52]. Diﬀerent modes of
cell death are known to play a role in hepatic IRI [8, 20]. For a
successful therapy of hepatic IRI, it is important to know
which mode of cell death takes place and which pathophysi-
ological mechanism underlies this damage. Apoptosis is still
being considered as one of the main forms of cell death after
hepatic IRI although several diﬀerent studies now show that
there is substantial overlap with other forms of regulated
necrotic cell death, for example, due to partially overlapping
mechanisms such as mitochondrial membrane transitions
[20, 53]. Regulated forms of necrosis in hepatic IRI are widely
regarded to elicit an inﬂammatory response unlike apoptosis.
Due to the rupture of the plasma membrane, necrosis
results in release of intracellular constituents (i.e., alarmins,
DAMPs) in the extracellular environment, which in turn
activate innate immune cells [54]. This may represent a prob-
able reason for IRI being correlated to a higher incidence of
acute rejection after liver transplantation [55]. Apart from
this, newly described alternative cell death pathways, pre-
dominantly necroptosis and ferroptosis, have gained consid-
erable relevance in models of oxidative stress and tissue
injury in recent years [9]. However, its precise role in the con-
text of liver ischemia remains to be deﬁned.
Nonetheless, the apoptotic fraction of hepatic IR injury
still takes an even more important position in most of the
current study models as potential proapoptotic enzyme path-
ways are relatively well measurable, thus creating a practica-
ble approach towards cell death. However, former studies
have not yet been able to fully show which exact pathways
actually underlie the mediated cell death resulting in hepatic
IRI. The consequent approach towards a scientiﬁc discrimi-
nation between the diﬀerent types of cell death may be the
elucidation of speciﬁc signaling cascades and thus deﬁning
the role of cell death under IR conditions.
Our data show that application of Baicalein, which acts
via inhibition of 12/15-LOX besides its antioxidant function,
signiﬁcantly decreases cell death in a murine hepatic IRI
model. Although our data does not prove any speciﬁc type
of cell death model, we hypothesize that cell death in our
experiments is primarily not caused by unregulated necrosis,
as necrosis normally takes more than 3 hours to become
apparent [53]. More likely, other types of cell death, such as
necroptosis or the recently described mechanism of ferropto-
sis, may represent the underlying mechanism. The hypothe-
sis of ferroptosis is supported by the results obtained by Xie
et al. in 2016, in which beneﬁcial eﬀects of Baicalein on fer-
roptosis in pancreatic cancer could be demonstrated [56].
We thus speculate in line with previous ﬁndings in hepatic
cells [57] that the GPX4-dependent death signaling, in which
12/15-LOX is still considered to represent one of the key
enzymes leading towards cell death, does play a major role
in hepatic IRI. Moreover, the central role of GPX4 in ferrop-
totic cell death has been thoroughly investigated in the past
years [11, 58, 59]. Regarding these data and taking Seiler
et al.’s and Loscalzo’s results of 2008 into account, it might
legitimately be hypothesized that sustained oxidative stress
initiated by ischemia-reperfusion on the one hand leads to
an impairment of GPX4 function and as a consequence stim-
ulates the activation of 12/15-LOX increasing the so-called
intracellular peroxide tone [23, 26]. Our data further suggest
that the majority of hepatic IR injury is aﬀected by more than
just necrosis and alternative cell death pathways including
apoptosis as also several proapoptotic enzymes were found
to be signiﬁcantly altered.
In 2008, AIF translocation was described as the main
eﬀector leading to cell death, whereas more recent studies
have casted doubts about this hypothesis. 12S-HpETE, the
product of activated 12/15-LOX, was pointed out as a possi-
bly relevant mediator for caspase-independent cell death via
AIF translocation, as no caspase-3 activation could be
detected in GPX4-knockout cells [23, 26]. On the other hand,
other studies have depicted caspase-3 as one of the key medi-
ators in hepatic IRI [60, 61], so in vivo situation might be dif-
ferent. Our data show that the inhibiton of 12/15-LOX by
Baicalein treatment of mice leads to a signiﬁcant decrease
of caspase-3, PARP, and JNK activation in liver tissue. We
suggest that these players need to be considered as in a
caspase-dependent setting as a part of the whole model of
hepatic IRI. While we still consider ERK1/2 as a relevant
mediator of hepatic IR injury, although it did not reach
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Figure 5: Quantiﬁcation of spectral photometric analyses of
intracellular activity of glutathione oxidation using Tietze’s kinetic
test. Activity was calculated as a ratio of measured amount of
oxidized glutathione disulﬁde (GSSG), the product of GPX4, over
its substrate glutathione (GSH). Pretreatment with Baicalein
showed a signiﬁcant increase in glutathione oxidation by +54.5%
(∗p = 0 0438), DMSO solely in a more discrete fashion (+16.7%).
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statistical signiﬁcance, kinetic analyses of ERK have shown
that the phosphorylation of ERK peaks within the ﬁrst 20
minutes after the cell death stimulus, followed by a rather
quick decay [62]. Our in vivo model thus indicated a ten-
dency in negative regulation of ERK1/2 activation with the
apoptotic stimulus being oxidative stress at the reperfusion
phase. As this tendency was still measurable in a relevant
manner even after 90 minutes post stimulus, we propose this
pathway to be relevant in hepatic IRI. However, from our
experience and regarding the most recent ﬁndings concern-
ing the importance of GPX4 in ferroptosis, we consider that
apoptosis is not the sole form of cell death under the condi-
tions of hepatic warm ischemia. Other forms of regulated cell
death, such as necroptosis and ferroptosis, thus have to be
considered as well. Due to their previously described role in
cell death development in IRI [61, 63], PARP and caspase-3
might hypothetically be relevant cell death mediators in the
described pathways. JNK and ERK are known to be broad
indicators of cell stress response and therefore located
upstream [64, 65], so that the antioxidant inﬂuence of Baica-
lein might most probably explain their decrease after pre-
treatment. The exact correlation between certain mediators
and respective forms of cell death that occur in hepatic IRI
is still to be scrutinized in future experiments.
Glutathione hemostasis is known to have a direct
inﬂuence on oxidative stress and its eﬀects in IRI [34].
This study showed that an upregulation of glutathione
biosynthesis is directly associated with a decreased amount
of cell death, leading to decreased liver damage after hepatic
IRI. As reviewed recently by Rodriguez-Lara et al., the rele-
vance of oxidative stress in IRI was pointed out as the forma-
tion of ROS is one of the main events leading to organ
damage [8]. We therefore state that the beneﬁcial eﬀects of
12/15-LOX inhibition observed in this study must primarily
be considered a reduction of oxidative stress, potentially
inﬂuenced by GPX4 enhancement and furtherly leading to
lesser ROS formation.
DMSO was used as the carrier solution for Baicalein in
this study. DMSO has already been described being hepato-
protective in several previous studies [66, 67]. Until now,
the protective eﬀects of DMSO in IRI have been imputed to
decreased Kupﬀer cell activation and leukocyte adhesion
[68], as well as restoration of vitamin C levels attenuating
oxidative stress [69]. The important role of Kupﬀer cells in
hepatic IRI [70] and their association with reactive oxygen
species [12, 71] have already been shown. Our data suggest
that DMSO might also have a direct eﬀect on hepatic IRI
by decreasing the number of dying cells and slightly enhanc-
ing glutathione oxidation itself. We could show that DMSO
application led to a reduced loss of cell viability on one hand.
On the other hand, it decreased the activation levels of PARP
and JNK after hepatic ischemia and reperfusion, yet in a
more discrete manner than Baicalein. Nonetheless, Baicalein
treatment resulted in signiﬁcantly lowered cell death,
potentially due to its eﬀects on caspase-3 and ERK1/2
which were not aﬀected by DMSO pretreatment. We thus
hypothesize that DMSO might interfere with the described
death pathway, yet not in the same and eﬃcient way as inhi-
bition of 12/15-LOX. This might be—in contrast to Baicalein
pretreatment—due to the lack of alteration in caspase-3
activity, one of the hepatic IRI’s key enzymes [60, 61].
In general, our data support the models of antagonistic
interaction between 12/15-LOX and GPX4 that have been
described previously [23, 26]. As Baicalein is known to be
an eﬀective inhibitor of 12/15-LOX [40], we could show that
Baicalein administration indeed leads to signiﬁcant protec-
tion against postischemic hepatic cell death by reduction of
oxidative stress. This results in increased glutathione oxida-
tion, as measured by a relatively bigger amount of its oxidized
product GSSG versus the reduced substrate GSH. As GPX4
has been described to directly decrease the peroxide tone
within the cell by reducing ROS which are potent activators
of 12/15-LOX [23], it may be speculated that Baicalein not
only decreases the peroxide tone by its antioxidant eﬀects
but also by increasing glutathione metabolism, hence pre-
sumably GPX4 activity. Both eﬀects cause a decreased
12/15-LOX activation. The exact mechanisms of cell death
induction by 12/15-LOX still have to be precisely elucidated
(i.e., by means of KO individuals within the experiments)
also in light of the fact that hepatocyte-speciﬁc deletion of
GPX4 causes massive cell death of hepatocytes and perinatal
lethality of mice [57].
Having pointed out the protective eﬀects following Baica-
lein and DMSO administration, we could also demonstrate
that the administered agents lead to a signiﬁcant increase of
transaminases and glutamate dehydrogenase in sham-
operated mice. We interpret this adverse eﬀect induced by
DMSO and Baicalein themselves. Although this could point
to conﬂicting results as opposed to the protective eﬀects men-
tioned above, an increase of TUNEL positivity could not be
monitored. Therefore, we conclude that the administered
agents provoke some cell damage without aﬀecting liver syn-
thesis, biliary excretion, or renal function resulting in a
release of hepatic enzymes without aﬀecting cell structures
relevant in inducing cell death. Several previous studies
regarding the potential toxicity of DMSO support our obser-
vations of transaminase elevation [72], especially when tak-
ing into account that we used a high dosage of DMSO
(6600mg/kg body weight) in order to allow dosing of high
concentrations of Baicalein (120mg/kg body weight i.p.) at
maximum solubility in DMSO in this proof-of-principle
experiment. The applied dosage of Baicalein is well estab-
lished as it has been used in previously described animal
studies [73, 74], and preliminary dosage ﬁnding experiments
of our study group showed no signiﬁcant impact at lower
concentrations. Previous studies regarding the protective
eﬀects of DMSO on hepatic ischemia and reperfusion used
signiﬁcantly lower dosages (500mg/kg b.w.), which did not
lead to elevated AST, ALT, and GLDH levels [66, 67]. Our
observations relating to toxicity of DMSO and Baicalein were
substantiated as a brief decrease in blood pressure with a con-
comitant increase of heart rate could be monitored after drug
administration. Although quickly self-limiting, one could
describe this eﬀect as drug toxicity of DMSO with or without
Baicalein. Baicalein has been described to aﬀect mitochon-
drial bioenergetics at high concentration and long exposure
[75], as well as to increase toxic eﬀects of other drugs like
cisplatin by enhancing gap junction communications [76].
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However, the concentration and exposure time in the present
experiment was by far lower. Even though these results pro-
vide an indication of Baicalein’s adverse eﬀects, a thorough
and suﬃcient insight in the toxicity of Baicalein is yet lacking.
Our hypothesis is supported by the observation that this
increase of laboratory parameters measured in blood samples
after DMSO or Baicalein could also be demonstrated in the
IRI-induced mice groups. However, the increase of transam-
inase and GLDH, calculated as the relative increase in
enzyme activation, was up to four times lower than between
the sham-operated groups after Baicalein treatment. This
facilitates the hypothesis that the signiﬁcantly reduced
increase of liver enzymes might be due to the cell protective
eﬀects as mentioned before. Concordantly to our previously
described results, this became more evident after Baicalein
pretreatment than after sole DMSO application, predomi-
nantly in AST and GLDH levels. However, whether the
toxic eﬀects of a therapy targeting 12/15-LOX qualiﬁes its
protective value in long term concerning hepatic IRI is yet
to be investigated.
Conclusively, it can be stated that the inhibition of 12/15-
LOX prevents cell death caused by hepatic IRI by sustaining
glutathione hemostasis—presumably involving GPX4—ther-
efore attenuating oxidative stress. Furthermore, our results
suggest that the 12/15-LOX-dependent signaling cascade
might relevantly impact on the key enzymes JNK, caspase-
3, PARP, and ERK and thus plays a major role within the
development of hepatic IRI. After further scientiﬁc evalua-
tion, this could be considered as a starting point for develop-
ing therapeutic approaches to minimize hepatic IRI in major
liver surgery and OLT, as long as a reasonable relation
between toxicity and protectiveness can be achieved.
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